A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.

3 weeks ago 58

Bristol Myers’ stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer’s treatment, even though the outcome of a late-stage trial has been delayed.

Read Entire Article

A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.

Related

It’s time for a retirement checkup: 5 easy ways to stay on t...

These stocks fell hard in 2025, but analysts see as much as ...

Why Lululemon founder Chip Wilson wants to shake up the boar...

Trending

Popular

Here’s what’s worth streaming in December 2025 on Netflix, H...

Meet the Billion-Dollar Crypto Founder Who Started Trading a...

Fed rate-cut bets surge: Can Bitcoin finally break $91K to g...

Most Ethereum valuation models indicate ETH is undervalued: ...

Ethereum Developers Prep for Fusaka, Second Upgrade of 2025

BlackRock exec says ‘perfectly normal’ as IBIT sees $2.3B ou...

Salesforce cheers ‘a powerful pipeline of future revenue’ as...

What mNAV Really Tells You About Bitcoin Treasury Companies ...

Strategy will sell Bitcoin as ‘last resort’ if mNAV drops, c...

ETH may reclaim $3.2K soon, based on low stablecoin yields: ...